Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma: a Phase II Trial (ANZUP 1601)

NCT03280667 is registered in ClinicalTrials.gov with Australian and New Zealand Urogenital and Prostate Cancer Trials Group as lead sponsor.

NCT NCT03280667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03280667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma: a Phase II Trial (ANZUP 1601)
Lead sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase
Phase 2
Overall status
Unknown status
Start date
December 12, 2017
Completion date
June 4, 2023
Enrollment
59 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic kidney cancer, renal cell carcinoma, clear cell